Zydus Lifesciences announced strong unaudited consolidated financial results for Q2 FY26. Revenue from operations reached Rs. 61,232 mn, a 17% increase year-over-year. EBITDA grew by 38% to Rs. 20,158 mn, with a margin of 32.9%. Net profit stood at Rs. 12,586 mn, up 38% YoY, reflecting strong performance across key business segments and geographies.
Financial Performance in Q2 FY26
Zydus Lifesciences reported a robust financial performance for the second quarter of fiscal year 2026. Here’s a summary of the key highlights:
- Revenue from operations: Rs. 61,232 mn, up 17% year-over-year.
- EBITDA: Rs. 20,158 mn, a 38% increase YoY, with EBITDA margin at 32.9%, an improvement of 500 bps.
- Net Profit: Rs. 12,586 mn, up 38% compared to the previous year.
- R&D investments for the quarter: Rs. 4,820 mn (7.9% of revenues).
- Capex (organic) for the quarter: Rs. 4,911 mn.
H1 FY26 Financial Highlights
The company also demonstrated strong results for the first half of FY26:
- Revenue from operations: Rs. 1,26,969 mn, up 11% over last year.
- EBITDA: Rs. 41,043 mn, a 16% increase YoY. EBITDA margin stood at 32.3%, an improvement of 130 bps.
- Net Profit: Rs. 27,254 mn, up 17% YoY.
- R&D investments: Rs. 9,676 mn (7.6% of revenues).
- Capex (organic) for the half year: Rs. 8,931 mn.
- Net Debt to Equity ratio as of September 30, 2025: 0.09x. Net Debt to EBITDA stood at 0.3x.
Business Segment Performance
A breakdown of business-wise sales performance in Q2 FY26:
- India Formulations: Rs. 15,931 mn, up 8.4% YoY.
- Consumer Wellness: Rs. 6,374 mn, up 30.7% YoY.
- US Formulations: Rs. 27,437 mn, up 13.5% YoY.
- International Formulations: Rs. 7,513 mn, up 39.4% YoY.
- Medtech: Rs. 1,532 mn.
- APIs: Rs. 1,472 mn, up 23.3%.
Key Business Updates
- India formulations business accounted for 26% of consolidated revenues. Branded formulations grew faster than the market, up 9% YoY.
- Consumer Wellness registered revenues of Rs. 6,374 mn, up 31% YoY, accounting for 11% of revenues.
- US formulations revenue reached Rs. 27,437 mn, up 14% YoY, representing 45% of consolidated revenues.
- International Markets formulations business reported revenues of Rs. 7,513 mn, up 39% YoY, contributing 12% to consolidated revenues.
Innovation and Pipeline
The company reported positive topline results from the pivotal Phase 2(b)/3 clinical trial of Saroglitazar Magnesium for Primary Biliary Cholangitis (PBC) in the US market and is preparing to file a New Drug Application (NDA) in Q4 FY26.
Source: BSE
